Skip to content

pAdVAntage Vector

by Promega
Login to view price.
Size
  • Overview
  • Protocols
  • Specifications
  • Resources
  • Co-transfection of mammalian cells with the pAdVAntage™ Vector enhances transient protein expression in a variety of cell types by increasing translation initiation. Luciferase constructs co-transfected with the pAdVAntage™ Vector showed at least a tenfold increase in luciferase expression in 293 and HeLa cell lines over transfections performed with the construct DNA alone.

    Transfection of mammalian cells with an expression vector often results in suboptimal expression of the protein of interest. Double-stranded RNA (dsRNA) generated during transfection is thought to activate the dsRNA-activated inhibitor (DAI), one of several enzymes involved in the host cell's antiviral defense system. DAI phosphorylates the translation initiation factor eIF-2, halting translation and therefore protein production.

    However, DAI translation inhibition can be overcome with the adenoviral Virus Associated I RNA (VAI RNA) produced by RNA polymerase III following co-transfection with the pAdVAntage™ Vector. The VAI RNA binds to DAI, preventing its activation, thereby allowing translation and protein expression.

    References

    1. Farrell, P.J. et al. (1977) Cell 11, 187–200.
    2. Groskreutz, D. and Schenborn, E. (1994) Promega Notes 48, 8–12.
    3. Kitajewski, J. et al. (1986) Cell 45, 195–200.
    4. O'Malley, R.P. et al. (1986) Cell 44, 391–400.

     

    Sequence Information

    pAdVAntage™ Vector GenBank® Accession Number U47294 and vector sequence text file.

  • Protocols

    Complete Protocol

    Download PDF

    pAdVAntage™ Vector Technical Bulletin

    PDF (186 KB)

  • Certificate of Analysis

    Lookup Certificate of Analysis

    Storage Conditions

    -30C TO -10C

    Use Restrictions

    For Research Use Only. Not for Use in Diagnostic Procedures.

  • Resources

    Citations